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OBJECTIVE—We investigated in a cross-sectional study the levels of serum and urinary
damage markers in diabetic patients (n = 94) and nondiabetic control subjects (n = 45) to study
theassociationofglomerular(IgG),proximaltubular(kidneyinjurymolecule[KIM]-1,N-acetyl-
b-D-glucosaminidase [NAG], neutrophil gelatinase–associated lipocalin [NGAL], and cystatin
C), and distal tubular (heart fatty acid–binding protein [H-FABP]) damage markers with kidney
disease severity, as assessed by albuminuria and estimated glomerular ﬁltration rate (eGFR).
RESEARCH DESIGN AND METHODS—Damage markers were measured in triplicate
in fresh morning urine samples and in plasma.
RESULTS—Of the diabetic patients, 41 were normoalbuminuric, 41 were microalbuminuric,
and 12 were macroalbuminuric. Urinary NAG (ninefold), NGAL (1.5-fold), and H-FABP (3.5-
fold) were signiﬁcantly elevated in normoalbuminuric diabetic patients compared with nondi-
abeticcontrolsubjects.Urinaryconcentrationsofallmarkersincreasedperalbuminuriastratum,
except KIM-1. All urinary damage markers, except KIM-1, were signiﬁcantly associated with
albuminuria, independent of age, sex, and plasma concentrations of the corresponding bio-
marker (standard bs between 0.35 and 0.87; all P # 0.001). All urinary damage markers, except
KIM-1, were signiﬁcantly associated with the eGFR in univariate models (standard bs between
20.38 and 20.21; all P , 0.04). After adjusting for age, sex, plasma concentration of the
corresponding damage marker, and albuminuria, only the association of H-FABP with eGFR
remained signiﬁcant (standard b 20.26; P =0 . 0 3 7 ) .
CONCLUSIONS—Glomerular and tubular markers are associated with albuminuria, inde-
pendently of eGFR, suggesting that albuminuria reﬂects both glomerular and tubulointerstitial
damage. Only urinary H-FABP is associated with eGFR independently of albuminuria and,
therefore, may be a promising urinary damage marker to assess diabetic kidney disease.
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D
iabetic nephropathy occurs in 20–
40%ofpatientswithdiabetesandis
the leading cause of chronic kidney
disease and end-stage renal disease in the
U.S. and many other Western countries
(1,2). The onset of elevated levels of uri-
nary albumin excretion is an early sign of
diabetic nephropathy. Various studies
haveshownthatinsubjectswithdiabetes,
microalbuminuria predicts the occur-
rence of macroalbuminuria and renal
function decline (3). As a result, high al-
buminuria has become an established re-
nal risk marker in these patients (4).
Classically, albuminuria is regarded
as the consequence of diabetes-induced
glomerular damage. More recently, it is
increasingly appreciated that the renal
tubulointerstitium plays a role in the
pathogenesis of diabetic nephropathy,
with prolonged exposure to a variety of
metabolic and hemodynamic injuring
factors associated with sustained diabetes
disease as contributing factors (5,6). Fur-
thermore,persistentalbuminuriasecond-
ary to glomerular lesions may be directly
harmful to renal tubular cells, leading to
tubular inﬂammation and tubulointersti-
tial ﬁbrosis (7,8).
Several tubular damage markers re-
cently have been discovered. Increased lev-
elsofthesemarkersaresupposedtoindicate




cystatin C and distal tubular damage in the
case of heart fatty acid–binding protein
(H-FABP). These tubular damage mark-
ers have been extensively investigated in
the ﬁeld of predicting the occurrence of
acute kidney injury after various nephro-
toxic insults, such as ischemia during car-
diac surgery, sepsis, and administration of
contrast medium (9–11). Little research
has been done in patients with chronic
kidney disease. In this study, we investi-
gated the serum and urinary levels of the
aforementioned damage markers in dia-
betic patients and nondiabetic control
subjectsinordertoinvestigatetherelation
of these markers to the severity of kidney
disease as assessed by albuminuria and
the estimated glomerular ﬁltration rate
(eGFR). As a secondary aim, we investi-
gated whether these damage markers
are related to eGFR independent of albu-
minuria.
RESEARCH DESIGN AND
METHODS—Type 1 and type 2 di-
abetic patients who were visiting a di-
abetes specialty clinic were recruited.
Inclusion was between April 2009 and
September 2009. They were stratiﬁed by
the amount of albuminuria, based on a
ﬁrst morning urine void. We included 94
diabetic patients, of whom 41 had nor-
moalbuminuria, 41 had microalbumin-
uria, and 12 had macroalbuminuria. To
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Pathophysiology/Complications
ORIGINAL ARTICLEensure that macroalbuminuria was the
consequence of diabetic nephropathy,
patients with macroalbuminuria were
required to have diabetic retinopathy. Pa-
tients who had cancer, infections or in-
ﬂammatory conditions, and renal disease
other than diabetic nephropathy; those
who used nephrotoxic drugs; those who
had a renal transplant; or those who were
pregnant were excluded. Patients aged
,18 years also were excluded. For a con-
trol group, we included 45 nondiabetic
subjects without chronic kidney disease
(1:2 vs. diabetic patients). Subjects were
excluded from the control group if they
had a fasting glucose .7.0 mmol/L, used
glucose-lowering medication, had an
eGFR ,60 mL/min per 1.73 m
2,o rh a d
an albumin-to-creatinine ratio (ACR)
.3 0m g / g .T h es t u d yp r o t o c o lw a sa p -
proved by the local ethics committee.
Measurements
Weinstructedpatientstocollecttheirﬁrst
morning urine void on the day of their
clinic visit. Blood pressure was assessed
w i t has i n g l em e a s u r e m e n t .U r i n a r ya l b u -
min concentration was determined by
nephelometry (BNII; Dade Behring Diag-
nostics, Marburg, Germany). Serum and
u r i n ec r e a t i n i n ew e r em e a s u r e dw i t ha n
enzymaticcreatinineassay(Roche,Mann-
heim, Germany). Glucose, HbA1c,a n d
cholesterol levels were measured with
standard laboratory testing.
Deﬁnitions
We deﬁned history of cardiovascular dis-
ease as having had a myocardial infarc-
tion, a stroke, surgery, or endovascular
treatment for coronary carotid or periph-
eral (legs, abdominal, and aorta) artery
disease. Hypertension was deﬁned as
systolic blood pressure .140 mmHg, di-
astolicbloodpressure.90mmHg,oruse
of blood pressure–lowering medication.
Normoalbuminuria was deﬁned as an
ACR ,3 mg/mmol, microalbuminuria
as an ACR 3–30 mg/mmol, and macro-
albuminuria as an ACR .30 mg/mmol
(12). Serum creatinine values were used
to calculate an eGFR, using the abbrevi-




marker; KIM-1, NGAL, NAG, and cysta-
tin CAs as markers of proximal tubular
damage;andH-FABPasamarker ofdistal
tubular damage. Urinary concentrations
of KIM-1, NGAL, H-FABP, and IgG were
measured by enzyme-linked immunosor-
bent assay. For KIM-1 and NGAL, anti-
bodies were obtained from R&D Systems
(Minneapolis, MN). H-FABP and IgG an-
tibodies were obtained from Hytest
(Turku, Finland). We measured urinary
concentration of NAG using a modiﬁed
enzyme assay according to Lockwood
and corrected for nonspeciﬁcc o n v e r s i o n
(HaemoScan, Groningen, the Nether-
lands). Cystatin C was measured by
nephelometry (reagents obtained from
Siemens [Marburg, Germany]). We mea-
s u r e da l ls a m p l e si nt r i p l i c a t ei nf r e s h
samples of both urine and plasma. Uri-
nary damage-marker concentrations are
expressed per millimole creatinine.
Statistical analyses
Analyses were performed with SPSS ver-
sion 16.0 (SPSS, Chicago, IL). Character-
istics were calculated per albuminuria
stratum. Parametric variables were ex-
pressed as means 6 SD, whereas non-
parametric variables were given as
median (interquartile range). We tested
P values for trend over albuminuria strata
indiabeticpatientsusingANOVAfornor-
mal distributed variables. For nonnormal
distributed variables, we used a Kruskall-
Wallistest.Logarithmictransformationof
damage-marker excretion was applied.
To investigate the association between
the individual damage marker and eGFR
or albuminuria, we performed a linear re-
gression analysis by using eGFR or albu-
minuria as independent variables and the
various damage markers as dependent
variables. Various models were gradually
built to adjust for possible confounding.
First, we investigated the crude associa-
tion between the damage marker and
eGFR or albuminuria. Second, we per-
formed multivariate analysis, adjusting
for age and sex. Third, we tested whether
plasma levels of the corresponding dam-
age marker inﬂuenced the association
between the damage marker and eGFR
or albuminuria. Finally, to investigate
whether knowledge about urinary damage-
marker concentrations may be of value
to assess the severity of diabetic kid-
ney disease in addition to knowledge
about albuminuria status, we performed
multivariable regression analysis with
eGFR as dependent variable and the dam-
age markers as independent variables, ad-
justingfor albuminuria. Weaddedthe use
of diuretics, the use of ACE inhibitors/
angiotensin receptor blockers (ARBs), and
the type of diabetes to the ﬁnal multivari-
able models (model 3 for albuminuria and
model4foreGFR)asasensitivityanalysis.
If any of these covariates showed a signif-
icant association with either albuminuria
or eGFR, we tested for interaction by en-
tering the urinary biomarker, the investi-
gated characteristic, and their product
term in the multivariable regression
model. For all analyses, a two-sided P ,
0.05 was considered statistically signiﬁ-
cant.
RESULTS—A total of 94 patients with
diabetes and 45 control subjects partici-
pated in this study. Characteristics of
patients and control subjects are given
in Table 1. Patients in the microalbumin-
uric and macroalbuminuric groups were
moreoftenmale andsmokers, moreoften
had a history of cardiovascular disease,
used more antihypertensive medications,
and had a lower eGFR when compared
with normoalbuminuric diabetic sub-
jects.
Damage-marker concentrations
Damage-marker concentrations in non-
diabetic control subjects and in diabetic
patients are shown in Table 2 and Fig. 1.
Urinary damage-marker concentrations
of NAG, NGAL, and H-FABP were higher
in normoalbuminuric patients with dia-
b e t e st h a ni nc o n t r o ls u b j e c t sa n di n -
creased with increasing categories of
albuminuria in patients with diabetes. In
contrast, cystatin C was lower in normo-
albuminuric diabetic patients than in
nondiabetic control subjects but again
increased with increasing categories of
albuminuria in patients with diabetes.
KIM-1 was higher in normoalbuminuric
patientswithdiabetesthanincontrolsub-
jects but was not different between the
categories of albuminuria in patients
with diabetes (Fig. 1 and Table 2). Differ-
ences between the categories of albumin-
uria were most pronounced for the
glomerular marker IgG (.30-fold in-
crease from normoalbuminuria to macro-
albuminuria) and the distal tubular
marker H-FABP (.21-fold). Differences
were less pronounced for the proximal
tubular markers (from no increase to an
8.5-fold increase for NGAL). Plasma con-
centrations of the various markers are
given in Supplementary Table 1.
Associations of damage markers with
albuminuria in diabetic patients
Associations between the various urinary
damage markers and albuminuria were
analyzed in all diabetic patients. All dam-
agemarkerswerefoundtobesigniﬁcantly
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Markers in patients with diabetesassociated with albuminuria in crude
models,exceptforKIM-1(Table3,model
1). Also, the results did not materially
change after adjusting for age and sex
(model 2) and, additionally, for the
plasma concentration of the correspond-
ing damage marker (model 3) and for
eGFR (model 4). All investigated damage
markers, except KIM-1, remained associ-
ated with albuminuria. When informa-
tion on use of diuretics, the use of ACE
inhibitors/ARBs, or the type of diabetes
was added to the multivariable regression
analyses, only the type of diabetes was a
signiﬁcant covariate for the association
between urinary KIM-1, NAG, NGAL,
cystatin C, and H-FABP with albumin-
uria. Sex was a signiﬁcant covariate in
only the association between NGAL and
albuminuria. We subsequently tested for
an interaction between these covariates
and these damage markers in their asso-
ciation with albuminuria. Of all tested in-
teraction terms, only the interaction
between sexand NGAL reached statistical
signiﬁcance.
Associations of damage markers
with eGFR in diabetic patients
Table 3 also shows the associations be-
tween the various urinary damage mark-
ers and eGFR. Again, all damage markers,
except KIM-1, were signiﬁcantly associ-
ated with eGFR in crude models (model
1). However, after adjusting for age and
sex, only albumin, the glomerular marker
IgG, the proximal tubular markers NGAL
and cystatin C, and the distal tubular
marker H-FABP remained signiﬁcantly
associated with eGFR (model 2). When
additionally adjusted for plasma con-
centration of the corresponding dam-
age marker, IgG, albumin, NGAL, and
H-FABP remained signiﬁcant, whereas
cystatin C lost signiﬁcance. The associa-
tion between the distal tubular marker
H-FABPandeGFRwastheonlyassociation
that remained signiﬁcant, after additional
Table 1—Characteristics of nondiabetic control subjects (n = 45) and diabetic patients (n = 94) according to albuminuria stratum
Nondiabetic
subjects
Subjects with diabetes P value in
diabetes Normoalbuminuria Microalbuminuria Macroalbuminuria
n 45 41 41 12
Age (years) 53 6 13 59 6 13 64 6 12* 63 6 13† 0.12
Male sex (%) 56 73 66 83 0.48
Diabetes duration (years) — 24 6 11 20 6 92 7 6 80 . 0 6 4
Type diabetes (% type 2) — 49 78 83 0.007
History of cardiovascular disease (%) 0 22 45 64 0.018
Smoking (%) 22 10 32 33 0.035
BMI (kg/m
2)2 7 6 63 0 6 5† 32 6 6‡ 32 6 5† 0.28
Systolic blood pressure (mmHg) 132 6 16 139 6 15† 141 6 17‡ 152 6 14* 0.052
Diastolic blood pressure (mmHg) 74 6 97 8 6 10 77 6 77 77 6 13 0.90
Antihypertensive medication (%) 18 72* 95* 100* 0.006
ACE inhibitors/ARBs (%) 4 65* 80* 83* 0.24
Diuretics 11 32* 63* 75* 0.015
Hypertension 36 85* 97* 100* 0.071
HbA1c (%) 5.4 6 0.3 7.7 6 1.0* 7.6 6 1.3* 7.8 6 0.7* 0.87
eGFR Modiﬁcation of Diet in Renal
Disease (mL/min per 1.73 m
2)8 6 6 14 85 6 21 72 6 22‡ 55 6 24‡ ,0.001
ACR (mg/mmol) 0.56 (0.44–1.0) 0.70 (0.36–1.21) 8.7 (5.6–13.7)* 115 (71–130)* ,0.001
Parametric variables are expressed as means 6 SD and nonparametric variables are median (interquartile range). *P , 0.001; †P , 0.05; ‡P , 0.01 vs. nondiabetic
control subjects, calculated using the independent-samples t test for normal distributed variables and the Mann-Whitney U test for nonnormal distributed variables.
Hypertension was deﬁned as systolic blood pressure .140 mmHg, diastolic blood pressure .90 mmHg, or use of antihypertensive medication.
Table 2—Damage-marker concentrations in nondiabetic control subjects and in diabetic patients according to albuminuria stratum
Nondiabetic
subjects
Subjects with diabetes P value in
diabetes Normoalbuminuria Microalbuminuria Macroalbuminuria
Albumin (mg/mmol) 0.56 (0.44–1.0) 0.70 (0.36–1.21) 8.7 (5.6–13.7)* 115 (71–130)* ,0.001
Glomerular
IgG (mg/mmol) 465 (279–867) 242 (151–751) 1,320 (590–3,780)‡ 7,379 (5,079–9,202)* ,0.001
Proximal tubular
KIM-1 (ng/mmol) 65 (33–104) 168 (116–216)* 122 (73–221)* 305 (112–417)* 0.53
NAG (units/mmol) 0.10 (0.07–0.14) 0.9 (0.6–1.4)* 1.2 (0.9–2.1)* 2.5 (1.4–3.4)* ,0.001
NGAL (mg/mmol) 1.3 (0.8–2.0) 2.1 (1.1–7.2)‡ 5.5 (2.9–14.0)* 18.0 (6.9–45.1)* 0.001
Cystatin C (mg/mmol) 4.2 (3.3–5.1) 2.6 (1.8–4.4)‡ 3.9 (2.7–5.0) 10.3 (6.7–33.3)* ,0.001
Distal tubular
H-FABP (ng/mmol) 34 (24–44) 130 (59–413)* 300 (104–1,215)* 2,742 (712–7,199)* ,0.001
Data are permmol urinary creatinine concentration and given as medians (25th–75th percentile). *P ,0.001;‡P ,0.01 vs. nondiabetic control subjects, calculated
using the Mann-Whitney U test.
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Nauta and Associatesadjustment for albuminuria (standard b
20.26; P = 0.037). When information
on sex, the use of diuretics, the use of
ACEinhibitors/ARBs,orthetypeofdiabe-
tes was added to the multivariable
regression analyses, only sex was a signif-
icant covariate for the association between
urinary cystatin C with eGFR, but no sig-
niﬁcant interaction was found between
sex and urinary cystatin C.
CONCLUSIONS—In the current
study, we measured markers of glomeru-
lar, proximal tubular, and distal tubular
damage to study therelationship between
these damage markers with the severity
of diabetic kidney disease as assessed by
albuminuria and eGFR. We found that
urinary concentrations of glomerular,
proximal tubular, anddistaltubular dam-
age markers were higher when patients
had more albuminuria. Interestingly,
even in normoalbuminuric diabetic pa-
tients some of these markers already were
elevated compared with nondiabetic sub-
jects. In regression analyses, all damage
markers that were signiﬁcantly associated
with albuminuria also were signiﬁcantly
associated with eGFR, except cystatin C
and NAG. H-FABP was the only damage
markersigniﬁcantlyassociatedwitheGFR
after adjustment for albuminuria.
In diabetic patients, the urinary con-
centration of the investigated glomerular
damage marker, IgG, increased over the
three albuminuria groups and is strongly
associated with albuminuria. In healthy
subjects,onlytraceamountsoftheselarge–
molecularweightproteinsareleakedbythe
glomerulus. These data suggest, therefore,
that in albuminuric diabetic patients, the
amount of albuminuria reﬂects glomerular
damage, at least to a certain extent. Similar
observations have been previously de-
scribed (13,14).
In general, all investigated tubular
markers, except KIM-1, increased in
higher albuminuria strata. Only a limited
number of studies have, to date, investi-
gated the association of tubular markers
with the severity of chronic kidney dis-
easeindiabeticnephropathy.Ourresults,
with respect to the proximal tubular
markers, are similar to these studies in-
sofar that they also showed that the
urinary level of tubular damage markers
parallels the degree of urinary albumin
excretion (15–18). It can be argued that
this may be a result of the tubulotoxic
effect of albumin and other proteins that
are leaked into the tubular lumen (7).
However, such tubulotoxic effects cannot
Figure 1—Biomarker concentrations in nondiabetic control subjects and in diabetic patients,
accordingtoalbuminuriastratum(normoalbuminuria,microalbuminuria,andmacroalbuminuria).
Box plots show medians (25th–75th percentile). Signiﬁcance was tested using the Mann-Whitney
Utest.Controlsubjectswereincludedwhensubjectshadafastingglucose,7.0mmol/Lordidnotuse
glucose-lowering medication.
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Markers in patients with diabetesfullyexplainourﬁndingsbecausesomeof
the markers under investigation already
were increased in the normoalbuminuric
diabetic patients compared with nondia-
beticcontrolsubjects,whereasalbuminuria
(and eGFR) in these normoalbuminuric
diabetic patients was comparable with
nondiabetic control subjects. A limited
numberofotherstudies(17–19)havepre-
viously described elevated levels of tubu-
lar markers in normoalbuminuric diabetic
subjects when compared with healthy
control subjects. Urinary excretion of
NGAL and lysosomal enzymes, such as
NAG and cathepsin, have, for instance,
been found to be increased. These data
suggest a role of the tubulointerstitium
in the pathogenesis and progression of re-
nal damage in patients with diabetes. This
assumption is strengthened by two other
observations in our study. First, we found
that some of these markers were associ-
ated with diabetes-related factors in nor-
moalbuminuric diabetic subjects, such as
BMI, duration of diabetes, and metabolic
regulation. Second, to our knowledge, we
are the ﬁrst to show that a marker of distal
tubular damage, H-FABP, also is associ-
ated with albuminuria, despite the fact
that the distal tubule is assumed to be
less sensitive to the toxic effects of urinary
proteins.
Data in literature also support the
ﬁndingthatindiabetickidneydisease,the
severity of chronic kidney disease de-
pends not only on the severity of glomer-
ular lesions but also on tubulointerstitial
damage.Ahistologicalstudy(20)showed
that proximal tubular basementmembrane
width already is thickened in normoalbu-
minuric diabetic patients compared with
healthy control subjects. Another study
(21) in microalbuminuric diabetic pa-
tients with similar GFR showed that only
29% had typical histological glomerular
features of diabetic nephropathy, whereas
42% had severe tubulointerstitial lesions
disproportional to the mild glomerular
involvement.
All markers that were associated with
albuminuria also were correlated with
eGFR in crude models. However, the
association of eGFR with the urinary
NAG concentration lost signiﬁcance after
adjusting for age and sex, and the associ-
ation with urinary cystatin C lost signif-
icance after additional adjustment for its
plasma concentration. In healthy sub-
jects, cystatin C is a marker for eGFR,
with impaired GFR being associated with
higherlevelsofcystatinC.Ourdataimply
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Nauta and AssociatesC is largely determined by the amount
that is ﬁltrated through the glomerulus in
subjects with diabetic nephropathy.
As secondary aim in our study, we
investigated which damage markers are
associated with eGFR independent of
albuminuria. Albuminuria is widely ac-
knowledged to be associated with eGFR
in subjects with diabetic nephropathy
(3,22). We found that the associations of
all markers under investigation with
eGFR lost statistical signiﬁcance after ad-
justing for albuminuria, except for
H-FABP. In addition, we found that the
urinary H-FABP concentration already
was signiﬁcantly elevated in normoalbu-
minuric patients with diabetes compared
with nondiabetic control patients who
had a similar eGFR. These data suggest
that urinary H-FABP concentration is a
promising marker to predict the clinical
outcomeofdiabeticnephropathy inaddi-
tion to albuminuria.
We acknowledge that the current
study has limitations. First, the current
study is a single-center study, and the
association of the measured damage
markers with albuminuria and eGFR
needstobeconﬁrmed.Second, thisstudy
has a cross-sectional design. Whether the
damagemarkers,asassessedinourstudy,
predict the progression of diabetic ne-
phropathy has to be investigated in long-
term, prospective, observational studies.
Finally, having a larger number of pa-
tients would have allowed us to perform
the analyses in speciﬁc subgroups. How-
ever, the results of our multivariable re-
gression analyses in which interactions
were tested showed that there were al-
most no signiﬁcant interactions between
these covariates and the various urinary
damage markers in their association with
albuminuria or eGFR. This suggests that
the associations between these damage
markers and albuminuriaoreGFR arenot
different in men versus women, in sub-
jects using or not using diuretics, in
subjects using or not using ACE inhib-
itors/ARBs, or in subjects with type 1
versus type 2 diabetes. The strengths of
this study are that we measured a wide
range of kidney damage markers, repre-
senting different parts of the nephron,
ranging from the glomerulus, proximal,
to distal tubules. Furthermore, we mea-
sured all our markers in fresh urine
samplestoensureoptimalsamplequality.
It has previously been shown for several
markers that frozen storage and freeze-
thaw cycles lead to a systematic decrease
and increase in variability (9,23,24),
which may negatively inﬂuence associa-
tion studies such as the present one. Fi-
nally, most authors investigating urinary
excretion of renal damage markers did
not measure plasma concentrations
(9,25). We also measured the corre-
sponding plasma concentration of all uri-
nary markers to rule out that a high
plasma concentration instead of renal
damage caused a high urinary concentra-
tion. This appeared to be the case for cys-
tatin C.
Inconclusion,urinaryconcentrations
of most investigated damage markers are
elevated in patients with diabetes when
compared with nondiabetic control sub-
jects. These damagemarkersare associated
with the severity of diabetic nephropathy
as assessed by albuminuria and eGFR.
Interestingly, some of these markers
already are elevated in normoalbuminu-
ric diabetic patients with normal eGFR.
This renders these proteins as potential
sensitive markers of early diabetic kidney
damage. Only the distal tubular marker
H-FABP was found to be associated with
eGFR independent of albuminuria, sug-
gesting that especially measuring uri-
nary H-FABP concentrations may be
useful to assess the severity of diabetic
kidney damage in addition to measuring
albuminuria.
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